Top 10 Sessions from the 2015 AACC Annual Meeting

2016 AMThank you for your AACC membership. Throughout 2016, you can turn to AACC for the most respected and up-to-date laboratory medicine resources and research.

As our gift to you, here are the most popular sessions from the 2015 Annual Meeting in Atlanta. In more than 14 hours of education, you’ll gain fresh insights and inspiration from the leaders in laboratory medicine.

Please share these recordings with your laboratory team and use them to introduce your colleagues to the many benefits of AACC membership. To download the sessions, click on either the session title link or the session graphic.

For more great education, mark your calendar for the 2016 AACC Annual Meeting, July 31-August 4 in Philadelphia.

Tackling HIV Latency: Towards a Cure for HIV

Tackling HIV Latency: Towards a Cure for HIVWhile there is excellent treatment available for HIV, treatment is lifelong and there is not a cure. The major goal of current research is to define the molecular and cellular mechanisms that lead to long term persistence of HIV on treatment, in the form of HIV latency and to use interventions that can reverse latency in patients on antiretroviral therapy. Recent advances in our understanding of latency and rare case reports of remission following cessation of treatment have raised optimism that a cure for HIV may be achievable.

Duration: 1 hour, 5 minutes

Next Generation Genomics and Personalized Medicine

Next Generation Genomics and Personalized MedicineNew omics technologies, including next generation sequencing, have revolutionized our understanding on the mutational landscape of cancer. The genomes of cancer cells, or DNA, obtained from tissues, circulating cells or circulating DNA can now be sequenced at unprecedented depth, at relatively low cost. These techniques allow for better selection of therapy and for avoidance of emergence of drug resistance in many patients. This session will discuss the opportunities and limitations of using high throughput genomics to select the most effective therapies.

Duration: 1 hour

Real-Time Resolution of Mutations That Cause Disease

Real-Time Resolution of Mutations That Cause DiseaseMolecular and genetic studies of inflammation and innate immunity have used mutagenesis to identify essential signaling molecules in the immune response and led to strategies to prevent, detect and treat various types of infections. Analogous approaches are used to investigate other types of diseases.

Duration: 1 hour, 11 minutes


Next-Generation Point-of-Care Diagnostics: Technologies, Design and Prototyping

Next-Generation Point-of-Care Diagnostics? Technologies, Design and Prototyping Novel point-of-care testing (POCT) technology and health information gathering is rapidly moving closer to the patient. Devices present in our everyday lives have begun to collect health information and are poised to play a greater role in the management of health and disease. This session presents three entrepreneur speakers from academia and industry with a focus on three different aspects of next-generation POCT technologies: 1) diagnostics embedded in consumer electronics; 2) novel biosensor for real-time monitoring; and 3) tools to move technologies from academia to commercialization.

Duration: 1 hour, 49 minutes

Developing a Successful IQCP: Let's Keep it Simple

Developing a Successful IQCP: Let's Keep it Simple Individualized Quality Control Plan (IQCP) is the alternative CLIA Quality Control option that will provide for quality control testing to meet regulatory requirements for non-waived testing. IQCP addresses the entire testing process: pre-analytic, analytic and post-analytic. Laboratories will be required to address applicable regulatory requirements in each of these phases for all tests. IQCP includes key concepts from CLSI EP-23 'Laboratory Quality Control Based on Risk Assessment', but it is NOT EP-23. It is a customized QC plan based on an individual laboratory's environment, test systems, personnel and patient population. It includes a risk assessment, a quality control plan, and quality assurance practices to monitor the plan. The intended goal of the new program is to identify, assess, and mitigate all potential errors in laboratories through all phases of testing, focusing on the 'right QC' for each test. This session will describe the components of the plan and provide ideas to create and implement the plan to meet Joint Commission requirements.

Duration: 1 hour, 27 minutes

From In Vitro to In Vivo Diagnostics - Are We Moving into the Body with Diagnostics?

From In Vitro to In Vivo Diagnostics - Are We Moving into the Body with Diagnostics? This session is intended to introduce the audience to the current and emerging clinical applications of nanotechnology. Nanotechnology allows for the creation of ever smaller diagnostic devices to the point where, one day, the line between in vivo and in vitro diagnostics will be obscured. For example, biosensors are used in today's POCT instrumentation and in the near future we will be able to measure the glucose concentration in our eye with the help of biosensor embedded in our contact lenses. In the not so distant future, submarine biosensors may reside in the blood stream and measure certain biochemical parameters. Where are nanotechnologies today and where will they be in the future? Attend this symposium and find out.

Duration: 1 hour, 18 minutes

The Clinical Chemist as a Clinical Consultant

The Clinical Chemist as a Clinical Consultant This session will outline the need and opportunities for an increased clinical consultative role for clinical chemists in health care settings, and summarize the work of the AACC in this area. The consultative role of the pharmacy profession and the transformation that led to this practice will be presented.

Duration: 1 hour, 21 minutes


Influence of Non-Glycemic Factors on Hemoglobin A1c: Fact and Fiction

There is considerable controversy concerning the clinical significance of different hemoglobin A1c values between different ethnic populations. The American Diabetes Association, the World Health Organization and other influential clinical groups have proposed that HbA1c 6.5% (48 mmol/mol) be used to diagnose diabetes for all patients. Other organizations advocate different HbA1c cutoffs for different ethnic and racial populations.

Duration: 1 hour and 12 minutes

President's Invited Session: Waking Up the General Public to the Importance of Laboratory Tests, Using Effective Story Telling (Including the Story of Caring for Ebola Patients at Emory University)

President's Invited Session: Waking Up the General Public to the Importance of Laboratory Tests, Using Effective Story Telling (Including the Story of Caring for Ebola Patients at Emory University)One of the greatest challenges in our profession is to be able to quickly and effectively convey the importance of clinical laboratory test results to the general public. Traditional modes of communication have not produced understanding of the value of laboratory medicine at levels needed to garner support from the public, other medical professionals, Congress and policy makers, and insurance companies. Thus, reimbursement for lab tests is often a target for cost-cutting, restricting physicians from ordering the tests they deem medically necessary for their patients. We, as laboratory professionals, must be better-equipped to communicate the value of laboratory medicine with all who will listen. This session presents storytelling as a proven approach to promoting the value of clinical laboratory medicine to a lay audience.

Duration: 2 hours, 6 minutes

Development of Pre-Clinical and Clinical Biomarkers

Development of Pre-Clinical and Clinical BiomarkersThis session will describe the development of emerging biomarkers from both a pre-clinical and clinical/industry perspective. The development of biomarkers for the assessment of hemostasis and deployment of these biomarkers in pharmaceutical research will be described. Interaction of the In Vitro Diagnostics (IVD) industry and the pharmaceutical industry in the development of companion diagnostics and precision medicine will be discussed.

Duration: 1 hour, 28 minutes